# Forge Genetics Announces Licensing Deal to Explore Forge Editing in Pharmaceutical Uses > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/gene-editing-pharmaceutical-applications-forge-genetics-deal/ > **Published:** 2026-04-07T07:02:54-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:28:33-04:00 > **Clinical Summary:** Forge Genetics announces a licensing deal to explore gene editing pharmaceutical applications with potential impact on cannabis therapeutics. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Biotechnology[Drug Development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/)Gene EditingPharmaceuticalsInnovation Why This Matters Gene editing technologies like CRISPR are increasingly being explored for pharmaceutical applications, potentially including cannabis-derived therapeutics. While this specific announcement lacks detail, the convergence of genetic engineering and pharmaceutical development could eventually impact how we approach cannabinoid-based medicines. Clinical Summary Forge Genetics has announced a licensing agreement to explore their gene editing platform for pharmaceutical applications, though specific therapeutic targets or timelines were not disclosed. Gene editing technologies are being investigated across multiple pharmaceutical sectors for their potential to enhance [drug development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/) and production processes. The clinical relevance to current [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice remains unclear given the limited information available about this particular platform or its intended applications. Dr. Caplan’s Take “Without knowing the specific pharmaceutical targets or mechanisms involved, this announcement represents early-stage technology development rather than actionable clinical information. I’ll be watching for concrete applications that might eventually impact [cannabinoid medicine](https://cedclinic.com/cannabinoids-prostate-cancer-anti-tumor-drugs/).” Clinical Perspective 🧠 Clinicians should maintain awareness of emerging biotechnologies that may influence future drug development, but this announcement does not change current clinical practice. Any eventual applications to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) would require rigorous clinical validation before implementation. Focus remains on evidence-based use of currently available cannabinoid therapeutics. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Forge%20Genetics%20announces%20licensing%20deal%20to%20explore%20Forge%20Editing%20in%20pharmaceutic...%20%40drcaplan&url=https%3A//www.selectscience.net/article/forge-genetics-announces-licensing-deal-to-explore-forge-editing-in-pharmaceutical-uses)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.selectscience.net/article/forge-genetics-announces-licensing-deal-to-explore-forge-editing-in-pharmaceutical-uses)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Forge%20Genetics%20announces%20licensing%20deal%20to%20explore%20Forge%20Editing%20in%20pharmaceutic...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.selectscience.net/article/forge-genetics-announces-licensing-deal-to-explore-forge-editing-in-pharmaceutical-uses)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.selectscience.net/article/forge-genetics-announces-licensing-deal-to-explore-forge-editing-in-pharmaceutical-uses](https://www.selectscience.net/article/forge-genetics-announces-licensing-deal-to-explore-forge-editing-in-pharmaceutical-uses) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis research?](#What_is_the_clinical_relevance_rating_of_this_cannabis_research) - [What areas of biotechnology does this research cover?](#What_areas_of_biotechnology_does_this_research_cover) - [Why is this cannabis research considered newsworthy?](#Why_is_this_cannabis_research_considered_newsworthy) - [What does “Notable Clinical Interest” mean for healthcare providers?](#What_does_8220Notable_Clinical_Interest8221_mean_for_healthcare_providers) - [How does gene editing relate to cannabis medicine?](#How_does_gene_editing_relate_to_cannabis_medicine) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis research? This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests emerging findings or policy developments in cannabis medicine that are worth monitoring closely by healthcare professionals. #### What areas of biotechnology does this research cover? The research spans multiple biotechnology areas including drug development, gene editing, and pharmaceuticals. This interdisciplinary approach suggests advanced scientific methods are being applied to cannabis-related [medical research](https://cedclinic.com/cb2-receptor-agonist-parkinsons/). #### Why is this cannabis research considered newsworthy? The article is marked as “New” and falls under the CED Clinic’s cannabis news category. The combination of cutting-edge biotechnology applications with [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) represents significant developments in the field. #### What does “Notable Clinical Interest” mean for healthcare providers? This designation indicates that the findings have potential clinical applications that could impact patient care. Healthcare providers should pay attention to these developments as they may influence future treatment protocols or therapeutic options. #### How does gene editing relate to cannabis medicine? Gene editing technology is being applied to [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) to potentially enhance therapeutic compounds or develop more targeted treatments. This represents the intersection of advanced biotechnology with cannabis-based pharmaceutical development. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [New Clinical Insights on Cannabis and Patient Outcomes](https://cedclinic.com/new-clinical-insights-on-cannabis-and-patient-outcomes/) Explore recent clinical findings on cannabis and how they affect patient outcomes in medical practice. [Read More](https://cedclinic.com/new-clinical-insights-on-cannabis-and-patient-outcomes/) [Cannabis Bioscience International Holdings: CBIH Announces Patent-Related Scientific …](https://cedclinic.com/cannabis-bioscience-international-holdings-cbih-announces-patent-related-scientific/) Learn about recent patent developments in cannabis bioscience that may influence future therapies. [Discover More](https://cedclinic.com/cannabis-bioscience-international-holdings-cbih-announces-patent-related-scientific/) [What sets research-led cannabis developers apart?](https://cedclinic.com/what-sets-research-led-cannabis-developers-apart/) Understand the unique approaches of research-driven cannabis developers in advancing medical cannabis. [Find Out](https://cedclinic.com/what-sets-research-led-cannabis-developers-apart/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).